Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) Pty.

Vertex Pharmaceuticals (Australia) clinical programs — 41 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
159
Drugs
64
Patents
991
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Vertex Pharmaceuticals (Australia) projects

41 ClinicalTrials.gov programs sponsored by Vertex Pharmaceuticals (Australia).

Vertex Pharmaceuticals (Australia) has 41 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

41 programs

Clinical programs

  1. 14C-VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  2. ALS-002158

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule terminated

    1 trial

  3. ALS-002200

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule completed

    1 trial

  4. AVN-944 capsules for oral administration

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Leukemia

    phase 1 small molecule completed

    1 trial

  5. G060-A5

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  6. IXP

    Vertex Pharmaceuticals (Australia) Pty.

    Focal Segmental Glomerulosclerosis (FSGS)

    phase 1 small molecule completed

    1 trial

  7. IXP

    Vertex Pharmaceuticals (Australia) Pty.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  8. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  9. PegInterferon

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  10. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  11. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. Prednisone

    Vertex Pharmaceuticals (Australia) Pty.

    Drug Interactions

    phase 1 small molecule completed

    1 trial

  13. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  14. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  15. Telaprevir; Moxifloxacin; Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  16. Treatment sequence AB

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  17. VCH 916

    Vertex Pharmaceuticals (Australia) Pty.

    HCV Infection

    phase 1 small molecule completed

    1 trial

  18. VCH-222

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  19. VX-118

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  20. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Focal Segmental Glomerulosclerosis (FSGS)

    phase 1 small molecule completed

    1 trial

  21. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  22. VX-272

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    1 trial

  23. VX-433

    Vertex Pharmaceuticals (Australia) Pty.

    Narcolepsy Type 1 (NT1)

    phase 1 small molecule active

    1 trial

  24. VX-440

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  25. VX-509

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy

    phase 1 small molecule completed

    1 trial

  26. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    7 trials

  27. VX-581

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    1 trial

  28. VX-634

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha 1-Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  29. VX-668

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha-1 Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  30. VX-708

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 1 small molecule completed

    1 trial

  31. VX-708

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  32. VX-770

    Vertex Pharmaceuticals (Australia) Pty.

    In Development for Cystic Fibrosis

    phase 1 small molecule completed

    2 trials

  33. VX-828

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    2 trials

  34. VX-840

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Kidney Disease

    phase 1 small molecule completed

    1 trial

  35. VX-973

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    2 trials

  36. VX-985 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  37. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    6 trials

  38. Vanzacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  39. lumacaftor 200 mg q12h + ivacaftor 250 mg q12h

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  40. telaprevir (VX-950)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatic Insufficiency

    phase 1 small molecule completed

    1 trial

  41. telaprevir formulation A

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Vertex Pharmaceuticals (Australia) have?

41 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.